Patient heal thyself: Modeling and treating neurological disorders using patient-derived stem cells

Experimental Biology and Medicine

Volumn 238, Issue 3, 2013, Pages 308-314

  Ess, Kevin C ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Induced pluripotent stem cell; IPSC; Mesenchymal stem cell; Neural regeneration

Indexed keywords

4 AMINOBUTYRIC ACID; TRANSCRIPTION FACTOR PAX6;

AUTOIMMUNE DISEASE; BIPOLAR DISORDER; BONE MARROW TRANSPLANTATION; BRAIN DISEASE; CELL THERAPY; ELECTROPHYSIOLOGY; EPILEPSY; GENE MUTATION; GENETIC ENGINEERING; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE RESPONSE; MESENCHYMAL STEM CELL; MULTIPLE SCLEROSIS; NERVE CELL PLASTICITY; NERVE REGENERATION; NEUROLOGIC DISEASE; NEUROLOGY; NEUROSURGERY; PERSONALITY DISORDER; REGENERATIVE MEDICINE; RETT SYNDROME; REVIEW; SCHIZOPHRENIA; SPINAL CORD DISEASE; STEM CELL TRANSPLANTATION;

CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; EPILEPSY; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MESENCHYMAL STEM CELL TRANSPLANTATION; NERVOUS SYSTEM DISEASES; REGENERATIVE MEDICINE; SPINAL CORD INJURIES; STEM CELL TRANSPLANTATION;

EID: 84877662226     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370213480713     Document Type: Review

References (69)

1. Burns A. Alzheimer's disease: on the verges of treatment and prevention. Lancet Neurol 2009;8:4-5
2. Becker RE, Greig NH, Giacobini E. Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices? J Alzheimer's Dis 2008;15:303-325
3. Priddle H, Jones DR, Burridge PW, Patient R. Hematopoiesis from human embryonic stem cells: overcoming the immune barrier in stem cell therapies. Stem Cells 2006;24:815-824
4. Leslie M. The action behind the words: embryonic stem cell research marches on. J Cell Biol 2006;174:743-746
5. Keller G. Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes Dev 2005;19:1129-1155
6. Gerecht-Nir S, Itskovitz-Eldor J. Cell therapy using human embryonic stem cells. Transpl Immunol 2004;12:203-209
7. Hochedlinger K, Jaenisch R. Nuclear transplantation, embryonic stem cells, and the potential for cell therapy. N Engl J Med 2003;349:275-286
8. Wade N. Government Proposes Regulations for Embryo Cell Research. The New York Times. 2001, 2 December 1999
9. Sullivan W. Frontiers of Science. From Microcosm to Macrocosm. The New York Times. 24 February 1976
10. Amit M, Carpenter MK, Inokuma MS, Chiu CP, Harris CP, Waknitz MA, Itskovitz-Eldor J, Thomson JA. Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Dev Biol 2000;227:271-278
11. Carpenter MK, Inokuma MS, Denham J, Mujtaba T, Chiu CP, Rao MS. Enrichment of neurons and neural precursors from human embryonic stem cells. Exp Neurol 2001;172:383-397
12. Mummery C, Ward-van Oostwaard D, Doevendans P, Spijker R, van den Brink S, Hassink R, van der Heyden M, Opthof T, Pera M, de la Riviere AB, Passier R, Tertoolen L. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 2003;107:2733-2740
13. Freeman TB, Willing A, Zigova T, Sanberg PR, Hauser RA. Neural transplantation in Parkinson's disease. Adv Neurol 2001;86:435-445
14. Storch A, Sabolek M, Milosevic J, Schwarz SC, Schwarz J. Midbrain-derived neural stem cells: from basic science to therapeutic approaches. Cell Tissue Res 2004;318:15-22
15. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-676
16. Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc 2007;2:3081-3089
17. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318:1917-1920
18. Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel R, Goland R, Wichterle H, Henderson CE, Eggan K. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008;321:1218-1221
19. Sommer CA, Stadtfeld M, Murphy GJ, Hochedlinger K, Kotton DN, Mostoslavsky G. Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 2009;27:543-549
20. Marchetto MC, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y, Chen G, Gage FH, Muotri AR. A model for neural development and treatment ofRett syndrome using human induced pluripotent stem cells. Cell 2010;143:527-539
21. Somers A, Jean J-C, Sommer CA, Omari A, Ford CC, Mills JA, Ying L, Sommer AG, Jean JM, Smith BW, Lafyatis R, Demierre M-F, Weiss DJ, French DL, Gadue P, Murphy GJ, Mostoslavsky G, Kotton DN. Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells 2010;28:1728-1740
22. Zhang N, An MC, Montoro D, Ellerby LM. Characterization of human Huntington's disease cell model from induced pluripotent stem cells. PLoS Currents 2010;2:RRN1193
23. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, Beard C, Brambrink T, Wu LC, Townes TM, Jaenisch R. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007;318:1920-1923
24. McMahon FJ, Insel TR. Pharmacogenomics and personalized medicine in neuropsychiatry. Neuron 2012;74:773-776
25. Lyon GJ. Personalized medicine: bring clinical standards to human-genetics research. Nature 2012;482:300-1
26. Longo DL. Tumor heterogeneity and personalized medicine. N Engl J Med 2012;366:956-957
27. Perez FA, Palmiter RD. Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci U S A 2005;102:2174-2179
28. Dolmetsch R, Geschwind DH. The human brain in a dish: the promise of iPSC-derived neurons. Cell 2011;145:831-834
29. Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2011;10:649-656
30. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010;67:1187-1194
31. Bonab MM, Sahraian MA, Aghsaie A, Karvigh SA, Hosseinian SM, Nikbin B, Lotfi J, Khorramnia S, Motamed MR, Togha M, Harirchian MH, Moghadam NB, Alikhani K, Yadegari S, Jafarian S, Gheini MR. Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: an open label study. Curr Stem Cell Res Ther 2012
32. Freedman MS, Uccelli A. Neurorepair with mesenchymal stem cells: hope or hype? Lancet Neurol 2012;11:123-125
33. Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cells as treatment for MS - progress to date. Mult Scler 2012
34. Croitoru-Lamoury J, Williams KR, Lamoury FM, Veas LA, Ajami B, Taylor RM, Brew BJ. Neural transplantation of human MSC and NT2 cells in the twitcher mouse model. Cytotherapy 2006;8:445-458
35. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K, Daley GQ. Disease-specific induced pluripotent stem cells. Cell 2008;134:877-886
36. Shi Y, Kirwan P, Livesey FJ. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat Protoc 2012;7:1836-46
37. Amenduni M, De Filippis R, Cheung AY, Disciglio V, Epistolato MC, Ariani F, Mari F, Mencarelli MA, Hayek Y, Renieri A, Ellis J, Meloni I. iPS cells to model CDKL5-related disorders. Eur J Hum Genet 2011;19:1246-1255
38. Katz DM, Berger-Sweeney JE, Eubanks JH, Justice MJ, Neul JL, Pozzo-Miller L, Blue ME, Christian D, Crawley JN, Giustetto M, Guy J, Howell CJ, Kron M, Nelson SB, Samaco RC, Schaevitz LR, St Hillaire-Clarke C, Young JL, Zoghbi HY, Mamounas LA. Preclinical research in Rett syndrome: setting the foundation for translational success. Dis Model Mech 2012;5:733-745
39. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-872
40. Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K, Shibata T, Kunisada T, Takahashi M, Takahashi J, Saji H, Yamanaka S. A more efficient method to generate integration-free human iPS cells. Nat Methods 2011;8:409-412
41. Kim D, Kim CH, Moon JI, Chung YG, Chang MY, Han BS, Ko S, Yang E, Cha KY, Lanza R, Kim KS. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009;4:472-476
42. Plews JR, Li J, Jones M, Moore HD, Mason C, Andrews PW, Na J. Activation of pluripotency genes in human fibroblast cells by a novel mRNA based approach. PLoS One 2010;5:e14397
43. Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y, Siuzdak G, Scholer HR, Duan L, Ding S. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009;4:381-384
44. Abyzov A, Mariani J, Palejev D, Zhang Y, Haney MS, Tomasini L, Ferrandino AF, Rosenberg Belmaker LA, Szekely A, Wilson M, Kocabas A, Calixto NE, Grigorenko EL, Huttner A, Chawarska K, Weissman S, Urban AE, Gerstein M, Vaccarino FM. Somatic copy number mosaicism in human skin revealed by induced pluripotent stem cells. Nature 2012;492:438-442
45. Hanna J, Cheng AW, Saha K, Kim J, Lengner CJ, Soldner F, Cassady JP, Muffat J, Carey BW, Jaenisch R. Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. Proc Natl Acad Sci USA 2010;107:9222-9227
46. Chamberlain SJ, Chen PF, Ng KY, Bourgois-Rocha F, Lemtiri-Chlieh F, Levine ES, Lalande M. Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader-Willi syndromes. Proc Natl Acad Sci USA 2010;107:17668-17673
47. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011;474:212-215
48. Hoche F, Seidel K, Theis M, Vlaho S, Schubert R, Zielen S, Kieslich M. Neurodegeneration in ataxia telangiectasia: what is new? What is evident? Neuropediatrics 2012;43:119-29
49. Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, Paz N, Koren-Michowitz M, Waldman D, Leider-Trejo L, Toren A, Constantini S, Rechavi G. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009;6:e1000029
50. Alderazi YJ, Coons SW, Chapman K. Catastrophic demyelinating encephalomyelitis after intrathecal and intravenous stem cell transplantation in a patient with multiple sclerosis. J Child Neurol 2012;27:632-635
51. Yemadje LP, Houinato D, Quet F, Druet-Cabanac M, Preux PM. Understanding the differences in prevalence of epilepsy in tropical regions. Epilepsia 2011;52:1376-1381
52. Stefan H. Epilepsy in the elderly: facts and challenges. Acta Neurol Scand 2011;124:223-237
53. Neligan A, Bell GS, Shorvon SD, Sander JW. Temporal trends in the mortality of people with epilepsy: a review. Epilepsia 2010;51:2241-2246
54. Ndimubanzi PC, Carabin H, Budke CM, Nguyen H, Qian YJ, Rainwater E, Dickey M, Reynolds S, Stoner JA. A systematic review of the frequency of neurocyticercosis with a focus on people with epilepsy. PLoS Neglect Trop Dis 2010;4:e870
55. Nash TE, Garcia HH. Diagnosis and treatment of neurocysticercosis. Nat Rev Neurol 2011;7:584-594
56. Lin JJ, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet 2012;380:1180-1192
57. Kvalsund MP, Birbeck GL. Epilepsy care challenges in developing countries. Curr Opin Neurol 2012;25:179-86
58. Bhalla D, Godet B, Druet-Cabanac M, Preux PM. Etiologies of epilepsy: a comprehensive review. Expert Rev Neurother 2011;11:861-876
59. Macdonald RL, Barker JL. Different actions of anticonvulsant and anesthetic barbiturates revealed by use of cultured mammalian neurons. Science 1978;200:775-7
60. Macdonald RL, McLean MJ. Anticonvulsant drugs: mechanisms of action. Adv Neurol 1986;44:713-36
61. Letinic K, Zoncu R, Rakic P. Origin of GABAergic neurons in the human neocortex. Nature 2002;417:645-649
62. Kriegstein AR. Constructing circuits: neurogenesis and migration in the developing neocortex. Epilepsia 2005;46(Suppl. 7):15-21
63. Fu C, Cawthon B, Clinkscales W, Bruce A, Winzenburger P, Ess KC. GABAergic Interneuron Development and Function Is Modulated by the Tsc1 Gene. Cerebral Cortex 2011;22:2111-9
64. Levitt P. Disruption of interneuron development. Epilepsia 2005;46(Suppl. 7):22-28
65. Powell EM, Campbell DB, Stanwood GD, Davis C, Noebels JL, Levitt P. Genetic disruption of cortical interneuron development causes region- and GABA cell type-specific deficits, epilepsy, and behavioral dysfunction. J Neurosci 2003;23:622-631
66. Calcagnotto ME, Ruiz LP, Blanco MM, Santos-Junior JG, Valente MF, Patti C, Frussa-Filho R, Santiago MF, Zipancic I, Alvarez-Dolado M, Mello LE, Longo BM. Effect of neuronal precursor cells derived from medial ganglionic eminence in an acute epileptic seizure model. Epilepsia 2010;51(Suppl. 3):71-75
67. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 2009;27:275-280
68. Neely M, Litt M, Tidball A, Li G, Aboud A, Hopkins C, Chamberlain R, Hong C, Ess KC, Bowman AB. DMH1, a highly selective small molecule bmp inhibitor promotes neurogenesis of hiPSCs: Comparison of PAX6 and SOX1 expression during neural induction. ACS Chem Neurosci 2012;3:482-491
69. Xu Q,Wonders CP, Anderson SA. Sonic hedgehog maintains the identity of cortical interneuron progenitors in the ventral telencephalon. Development 2005;132:4987-4998